Neuro-oncology · 2026
Improved coping and self-efficacy drive improvements in mood among caregivers of patients with primary malignant brain tumors: Results from a randomized controlled trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Willis Kelcie D, Forst Deborah A, Horick Nora, Strander Sumita M, Whitman Jessica, Corveleyn Amy, Sannes Timothy, Temel Jennifer S, Greer Joseph A, El-Jawahri Areej, Jacobs Jamie M
Аннотация
BACKGROUND: In a recent randomized controlled trial, caregivers of patients diagnosed with primary malignant brain tumors (PMBT) who received NeuroCARE-a 6-session, cognitive-behavioral, telehealth intervention-demonstrated improved anxiety and depression symptoms at 11 weeks post-randomization compared to caregivers assigned to usual care (UC). We explored whether these intervention effects were mediated by improvements in coping and self-efficacy.
METHODS: We examined data from caregivers of patients with PMBT randomized to receive either NeuroCARE or UC (N = 120). Participants completed assessments of anxiety and depression symptoms (Hospital Anxiety and Depression Scale), coping (Measure of Current Status), and self-efficacy (Lewis Cancer Self-Efficacy Scale) at baseline, 11 weeks, and 16 weeks. We conducted 4 simple mediation regression models using the Preacher & Hayes bootstrapping method to examine whether improvements in coping or self-efficacy from baseline to 11 weeks mediated intervention effects on 11-week anxiety or depression symptoms.
RESULTS: The sample (N = 120; Mage = 53 years) predominantly consisted of participants who self-identified as female (82.5%), White (91.7%), and spouses/partners (70.0%) caring for a patient with glioblastoma (84%). Improvements in 11-week anxiety symptoms in caregivers assigned to NeuroCARE were mediated by improved coping (indirect effect = -1.44, SE = 0.49, 95% CI [-2.50, -0.54]) and self-efficacy (indirect effect=-1.29, SE = 0.42, 95% CI [-2.16, -0.52]). Similarly, improvements in 11-week depression symptoms were mediated by improved coping (indirect effect=-1.43, SE = 0.38, 95% CI [-2.21, -0.74]) and self-efficacy (indirect effect = -0.95, SE = 0.32, 95% CI [-1.60, -0.36]).
CONCLUSION: The NeuroCARE intervention improves mood by enhancing coping skills and improving caregivers' self-efficacy in caregivers of patients with PMBT.
METHODS: We examined data from caregivers of patients with PMBT randomized to receive either NeuroCARE or UC (N = 120). Participants completed assessments of anxiety and depression symptoms (Hospital Anxiety and Depression Scale), coping (Measure of Current Status), and self-efficacy (Lewis Cancer Self-Efficacy Scale) at baseline, 11 weeks, and 16 weeks. We conducted 4 simple mediation regression models using the Preacher & Hayes bootstrapping method to examine whether improvements in coping or self-efficacy from baseline to 11 weeks mediated intervention effects on 11-week anxiety or depression symptoms.
RESULTS: The sample (N = 120; Mage = 53 years) predominantly consisted of participants who self-identified as female (82.5%), White (91.7%), and spouses/partners (70.0%) caring for a patient with glioblastoma (84%). Improvements in 11-week anxiety symptoms in caregivers assigned to NeuroCARE were mediated by improved coping (indirect effect = -1.44, SE = 0.49, 95% CI [-2.50, -0.54]) and self-efficacy (indirect effect=-1.29, SE = 0.42, 95% CI [-2.16, -0.52]). Similarly, improvements in 11-week depression symptoms were mediated by improved coping (indirect effect=-1.43, SE = 0.38, 95% CI [-2.21, -0.74]) and self-efficacy (indirect effect = -0.95, SE = 0.32, 95% CI [-1.60, -0.36]).
CONCLUSION: The NeuroCARE intervention improves mood by enhancing coping skills and improving caregivers' self-efficacy in caregivers of patients with PMBT.